Latest Breaking News On - Associated vasculitis - Page 8 : comparemela.com

Message : Required fields Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased ChemoCentryx, Inc. (NASDAQ: CCXI) securities between November 26, 2019 and May 3, 2021, inclusive (the “Class Period”). Investors have until July 6, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. The Class Period commences on November 26, 2019. After the market closed on November 25, 2019, ChemoCentryx issued a press release announcing “Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis.” Throughout the Class Period, the defendants lauded the results of the ADVOCATE Phase III trial, as well as the safety profile of avacopan for the tr

United statesBrandon walkerBragar eagel squireMelissa fortunatoMarion passmoreUnited states district courtDrug administrationChemocentryx incBragar eagelNorthern districtClass periodTopline dataPivotal phaseDemonstrating avacopanSuperiority over standardAssociated vasculitis